Buckhead Capital Management LLC Has $1.93 Million Holdings in Bruker Co. (NASDAQ:BRKR)

Buckhead Capital Management LLC decreased its position in shares of Bruker Co. (NASDAQ:BRKR) by 3.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 32,994 shares of the medical research company’s stock after selling 1,179 shares during the quarter. Buckhead Capital Management LLC’s holdings in Bruker were worth $1,934,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Stanley Laman Group Ltd. acquired a new position in Bruker in the fourth quarter valued at $5,229,000. Van ECK Associates Corp grew its holdings in Bruker by 48.8% during the 4th quarter. Van ECK Associates Corp now owns 84,004 shares of the medical research company’s stock worth $4,924,000 after acquiring an additional 27,553 shares during the period. Allspring Global Investments Holdings LLC raised its position in shares of Bruker by 1.8% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 214,580 shares of the medical research company’s stock worth $12,619,000 after acquiring an additional 3,819 shares in the last quarter. Savant Capital LLC lifted its stake in shares of Bruker by 44.9% in the 4th quarter. Savant Capital LLC now owns 26,440 shares of the medical research company’s stock valued at $1,550,000 after purchasing an additional 8,198 shares during the period. Finally, Vaughan Nelson Investment Management L.P. boosted its position in shares of Bruker by 140.3% during the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 1,141,762 shares of the medical research company’s stock valued at $66,930,000 after purchasing an additional 666,617 shares in the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Stock Down 1.0 %

Shares of NASDAQ BRKR opened at $51.15 on Friday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73. The company has a 50-day moving average price of $57.73 and a 200-day moving average price of $60.71. The stock has a market capitalization of $7.75 billion, a P/E ratio of 24.59, a P/E/G ratio of 3.81 and a beta of 1.16. Bruker Co. has a 1 year low of $48.07 and a 1 year high of $94.86.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.01. Bruker had a return on equity of 21.52% and a net margin of 9.41%. On average, equities research analysts forecast that Bruker Co. will post 2.4 EPS for the current fiscal year.

Analysts Set New Price Targets

BRKR has been the subject of a number of research analyst reports. UBS Group assumed coverage on Bruker in a report on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 target price for the company. Citigroup reduced their price objective on shares of Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. TD Cowen dropped their target price on shares of Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research report on Wednesday, November 6th. The Goldman Sachs Group upgraded shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price target for the company in a report on Thursday, December 5th. Finally, Guggenheim reiterated a “buy” rating on shares of Bruker in a report on Friday, January 17th. Six research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $74.09.

Insider Activity at Bruker

In other news, CEO Frank H. Laukien purchased 100,000 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The shares were bought at an average cost of $50.14 per share, with a total value of $5,014,000.00. Following the completion of the transaction, the chief executive officer now directly owns 38,439,563 shares of the company’s stock, valued at approximately $1,927,359,688.82. This trade represents a 0.26 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 28.30% of the stock is owned by insiders.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.